Journal: Journal of Virology

Article Title: Human Cytomegalovirus Decreases Major Histocompatibility Complex Class II by Regulating Class II Transactivator Transcript Levels in a Myeloid Cell Line

doi: 10.1128/JVI.01901-19

Figure Lengend Snippet: HCMV downregulates surface expression of MHC class II in a myeloid progenitor cell line. (A) Flow cytometry analysis of unstained Kasumi-3 cells or cells stained for HLA-DR, HLA-DQ, and HLA-DP. (B) Flow cytometry scatter plot of HCMV-infected (72 hpi) and uninfected cells showing the relationship between mCherry (a marker of HCMV infection) and HLA-DR. (C) Histograms of HCMV-infected (mCherry) and uninfected Kasumi-3 cells stained for surface HLA-DR at 72 and 120 h postinfection. (D) Bar graph of the geometric mean (GM) fluorescence values for the samples used in the assay whose results are presented in panel C, displayed as a percentage of the value for the uninfected sample. (E) Geometric mean fluorescence values from uninfected or HCMV-infected CD14+ human peripheral blood monocytes (HPBM) at 72 hpi. Values are averages from a minimum of three independent experiments. *, P < 0.05.

Article Snippet: Human peripheral blood monocytes (catalog number 6906K-50A; Cell Applications Inc.) were maintained in the manufacturer’s supplied human blood cell culture medium.

Techniques: Expressing, Flow Cytometry, Staining, Infection, Marker, Fluorescence

Journal: iScience

Article Title: Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1

doi: 10.1016/j.isci.2024.109576

Figure Lengend Snippet: Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy CD34 + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).

Article Snippet: Human Mobilized Peripheral Blood CD34 + Cells, used as healthy controls, were purchased from AMS Biotechnology (Europe) Limited.

Techniques: Inhibition, Western Blot, Standard Deviation, Cell Culture

Journal: iScience

Article Title: Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1

doi: 10.1016/j.isci.2024.109576

Figure Lengend Snippet:

Article Snippet: Human Mobilized Peripheral Blood CD34 + Cells, used as healthy controls, were purchased from AMS Biotechnology (Europe) Limited.

Techniques: Control, Virus, Recombinant, Modification, Saline, Stripping Membranes, Protease Inhibitor, Reverse Transcription, Membrane, Labeling, Gel Extraction, Plasmid Preparation, Software